Zynlonta, known generically as loncastuximab tesirine-lpyl, is a targeted cancer treatment for certain adults with large B-cell lymphoma that has returned or stopped responding to previous therapy. Its name may require a warm-up lap before pronunciation, but the treatment concept is easier to understand: Zynlonta finds lymphoma cells carrying the CD19 protein and delivers a powerful cancer-killing payload directly to them.
This medication is not a tablet taken at home. It is a prescription intravenous infusion prepared and administered by trained healthcare professionals. Because it can cause serious blood-count changes, infections, fluid accumulation, liver injury, and skin reactions, treatment requires regular laboratory testing and close communication with an oncology team.
Zynlonta Quick Facts
- Generic name: loncastuximab tesirine-lpyl
- Drug class: CD19-directed antibody-drug conjugate
- Administration: Intravenous infusion over approximately 30 minutes
- Schedule: Once every three weeks
- Approved patients: Adults with certain relapsed or refractory large B-cell lymphomas after at least two systemic treatment regimens
- Premedication: Dexamethasone is generally given around each infusion
- Available form: A single-dose vial containing 10 mg of white to off-white freeze-dried powder
What Is Zynlonta Used For?
Zynlonta is FDA approved for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. “Relapsed” means the lymphoma improved or disappeared after treatment but later returned. “Refractory” means the cancer did not respond adequately or continued growing despite treatment.
The approved indication includes:
- Diffuse large B-cell lymphoma, or DLBCL, not otherwise specified
- DLBCL that developed from a lower-grade lymphoma
- High-grade B-cell lymphoma
Zynlonta is generally considered a third-line or later treatment. However, the choice between Zynlonta, CAR T-cell therapy, bispecific antibodies, transplantation, another antibody-drug conjugate, or a clinical trial depends on much more than a treatment-line number. Doctors also consider prior therapies, CD19 expression, the speed and location of the relapse, organ function, age, daily functioning, and personal treatment goals.
Its safety and effectiveness have not been established in children. Zynlonta also should not be viewed as a universal treatment for every form of non-Hodgkin lymphoma simply because the disease contains B cells.
Accelerated FDA approval
Zynlonta received accelerated approval based on the percentage of patients whose tumors shrank in a clinical trial. Under this pathway, continued approval may depend on confirmatory research verifying clinical benefit. Accelerated approval does not mean the drug skipped safety review; it means an earlier clinical endpoint, such as response rate, supported availability while additional evidence is collected.
How Zynlonta Works
Zynlonta is an antibody-drug conjugate, often shortened to ADC. Think of it as a targeted delivery system with two major parts:
- A humanized monoclonal antibody recognizes and attaches to CD19, a protein found on the surface of many malignant B cells.
- The attached tesirine component carries SG3199, a highly potent pyrrolobenzodiazepine dimer that damages DNA.
After the antibody binds to CD19, the lymphoma cell pulls the drug-antibody complex inside. Enzymes then release the cytotoxic payload. SG3199 forms DNA cross-links, interfering with cell division and ultimately causing cell death.
This targeting helps concentrate treatment activity in CD19-expressing cells, but “targeted” does not mean “side-effect free.” Some of the payload can affect healthy tissues, and normal B cells may also express CD19. That is why blood counts, liver tests, infection symptoms, swelling, breathing changes, and skin reactions require careful monitoring.
Zynlonta Dosing and Administration
Standard recommended dosing schedule
Zynlonta is infused into a vein on the first day of each 21-day treatment cycle. The recommended dosage is:
- Cycles 1 and 2: 0.15 mg per kilogram of body weight once every three weeks
- Cycle 3 and later: 0.075 mg per kilogram once every three weeks
Each infusion is administered over approximately 30 minutes. Treatment may continue until the lymphoma progresses, side effects become unacceptable, or the oncology team determines that another strategy is more appropriate.
For patients with a body mass index of 35 kg/m² or higher, the current prescribing information directs clinicians to calculate the dose using adjusted body weight. This is strictly professional dose mathnot a do-it-yourself project involving a bathroom scale and an optimistic calculator.
Dexamethasone premedication
Unless medically contraindicated, dexamethasone 4 mg is given by mouth or intravenously twice daily for three days, starting the day before the Zynlonta infusion. If premedication was not started the previous day, dexamethasone should generally begin at least two hours before the infusion.
Dexamethasone helps reduce certain treatment reactions, particularly swelling and skin-related effects. Because steroids can raise blood sugar, disturb sleep, increase appetite, or affect mood, patients should tell the care team about diabetes, significant insomnia, psychiatric symptoms, or previous steroid intolerance.
When treatment may be withheld or changed
The treating team may delay, reduce, or permanently discontinue Zynlonta based on laboratory findings and symptoms. Examples from the prescribing information include:
- Holding treatment if the absolute neutrophil count falls below 1 billion cells per liter
- Holding treatment if platelets fall below 50,000 per microliter
- Holding treatment for moderate or worse edema or fluid accumulation until it improves
- Discontinuing treatment for severe pericardial effusion or certain recurrent heart-related effusions
- Withholding treatment for severe liver-enzyme elevation or suspected drug-induced liver injury
- Discontinuing Zynlonta if drug-induced liver injury is confirmed
If a toxicity-related delay lasts longer than three weeks, later doses may be reduced by 50%. The exact decision depends on the type, severity, duration, and recurrence of the reaction.
A missed or postponed infusion should be rescheduled by the oncology clinic. Patients should not attempt to “catch up,” because Zynlonta is neither a home medication nor a double-the-next-dose situation.
Common Zynlonta Side Effects
Side-effect statistics come from clinical trials and cannot predict exactly what will happen to one person. The most frequently observed reactions and laboratory abnormalities included:
- Low platelet counts
- Low neutrophil counts
- Anemia
- Elevated liver enzymes, including GGT, AST, and ALT
- High blood sugar
- Low albumin
- Fatigue or weakness
- Rash, itching, or sun sensitivity
- Swelling or fluid retention
- Nausea
- Diarrhea, constipation, vomiting, or abdominal discomfort
- Muscle, joint, back, neck, or limb pain
- Reduced appetite
In the pivotal LOTIS-2 trial, fatigue occurred in 38% of patients, rash in 30%, edema in 28%, nausea in 23%, and musculoskeletal pain in 23%. Laboratory abnormalities were also common: platelets decreased in 58%, neutrophils in 52%, and hemoglobin in 51% of patients.
These numbers include all severity levels. A mild laboratory change is not the same as a medical emergency, but trends matter. Oncology teams often react to laboratory results before a patient feels noticeably unwell.
Serious Warnings and Precautions
Effusions, edema, and capillary leak syndrome
Zynlonta can cause serious fluid accumulation, including swelling in the legs or elsewhere, abdominal fluid, pleural effusion around the lungs, and pericardial effusion around the heart. Rarely, severe pericardial fluid can interfere with heart function. Capillary leak syndrome, in which fluid and proteins escape from small blood vessels into surrounding tissues, has also occurred.
Contact the oncology team promptly for rapid weight gain, worsening swelling, abdominal bloating, dizziness, unusually low blood pressure, new chest pain, shortness of breath, or difficulty lying flat. These symptoms may require examination, laboratory tests, or imaging.
Bone marrow suppression
Zynlonta may substantially lower neutrophils, platelets, and red blood cells. Low neutrophils increase infection risk, low platelets increase bleeding risk, and anemia may cause fatigue, weakness, dizziness, or shortness of breath.
Complete blood counts are monitored throughout treatment. Some patients may need a treatment delay, dose reduction, transfusion, growth-factor support, or other medical care.
Serious infections
Severe and occasionally fatal infections, including pneumonia, sepsis, and opportunistic infections, have occurred. A fever during cancer treatment should never be saved for the next scheduled appointment.
Call the treatment team immediately for fever, shaking chills, worsening cough, sore throat, painful urination, confusion, rapidly increasing weakness, or red, warm, painful skin. Follow the clinic’s specific fever threshold; many centers instruct patients to report a temperature of 100.4°F, or 38°C, or higher immediately.
Liver injury
Zynlonta has been associated with cholestatic and hepatocellular liver injury, including severe, life-threatening, and fatal drug-induced liver injury. Liver-function tests should be checked before and during treatment.
Urgent warning signs include yellow skin or eyes, dark urine, pale stools, persistent nausea, right-upper-abdominal pain, unusual itching, or marked fatigue. Zynlonta should be avoided in severe hepatic impairment. Information remains limited for moderate hepatic impairment.
Skin reactions and photosensitivity
Serious rashes, blistering, exfoliative reactions, redness, and photosensitivity can occur. Patients should minimize direct natural and artificial sunlight, including intense light through windows. Protective clothing, a broad-spectrum sunscreen, shade, and avoidance of tanning devices are sensible precautions.
Report spreading rash, blistering, peeling, painful skin, open sores, or involvement of the eyes or mouth promptly. Postmarketing reports have also included visible small blood vessels, blistering, and vesicular rash.
Infusion-site tissue injury
Zynlonta must be infused into a vein. If the medication leaks into surrounding tissue, it may cause pain, swelling, irritation, or severe tissue damage. Tell the infusion nurse immediately about burning, stinging, pressure, itching, redness, or pain around the IV site. This is not the moment to be politely stoic.
Pregnancy and fertility risks
Zynlonta can harm an unborn baby. Pregnancy testing is recommended before treatment for patients who could become pregnant.
- Females of reproductive potential should use effective contraception during treatment and for 10 months after the last dose.
- Males with female partners of reproductive potential should use effective contraception during treatment and for seven months after the last dose.
- Breastfeeding is not recommended during treatment or for three months after the final dose.
Animal findings suggest the medication may impair male fertility. Patients concerned about future fertility should discuss sperm banking or other preservation options before therapy whenever circumstances allow.
Zynlonta Drug Interactions
The current U.S. prescribing information does not contain a standard section listing proven clinical drug interactions. That should not be translated into “Zynlonta interacts with nothing.” Formal interaction information is limited, and cancer patients often receive several medications whose side effects can overlap.
The cytotoxic component SG3199 is metabolized by CYP3A4 and CYP3A5 in laboratory studies and is a substrate of the P-glycoprotein transporter. At clinically relevant concentrations, it did not inhibit several major CYP enzymes or common transport proteins in laboratory testing. However, laboratory findings do not settle every real-world interaction question.
Before each cycle, provide the oncology pharmacist with a complete list of:
- Prescription medicines
- Over-the-counter pain relievers and cold products
- Vitamins and minerals
- Herbal remedies and concentrated extracts
- Antibiotics, antifungals, or antiviral medicines prescribed by another clinician
- Blood thinners or medicines affecting platelets
- Drugs that may suppress bone marrow or injure the liver
Alcohol may add stress to the liver or worsen dehydration and should be discussed with the treating team. Patients should also ask before receiving vaccines. Live vaccines are often avoided during significant immune suppression, while the timing and expected effectiveness of non-live vaccines may require individualized planning.
Dexamethasone deserves its own medication review because it can affect blood sugar, sleep, mood, infection risk, and stomach irritation. Patients with diabetes may need more frequent glucose monitoring around treatment days.
What Does Zynlonta Look Like?
Zynlonta is supplied as 10 mg of white to off-white freeze-dried powder in a single-dose vial. After a healthcare professional reconstitutes it, the solution should be clear to slightly opalescent and colorless to slightly yellow. It is then further diluted in an infusion bag before administration.
Patients normally will not store, mix, or handle Zynlonta at home. Packaging designs, label layouts, and vial photography can change, so online pictures should not be used to authenticate medication. Hospitals and specialty pharmacies verify the product using its name, strength, lot information, storage history, and approved supply chainnot by playing a pharmaceutical version of “spot the difference.”
If a patient sees the infusion bag, the absence of a bright color does not indicate that the medicine is weak or missing. The final solution is expected to be essentially colorless to slightly yellow.
How Effective Is Zynlonta?
FDA approval was based primarily on LOTIS-2, an open-label, single-arm study involving 145 adults with relapsed or refractory DLBCL or high-grade B-cell lymphoma after at least two previous systemic regimens.
The independently assessed overall response rate was 48.3%. The complete response rate was 24.1%, and another 24.1% achieved a partial response. Among responding patients, the median duration of response reported in the prescribing information was 10.3 months.
These findings are meaningful in a heavily pretreated population, but they do not guarantee that an individual patient will respond. The study did not randomly compare Zynlonta against another treatment, excluded certain patients such as those with active central nervous system lymphoma, and enrolled a population that was predominantly White. Treatment decisions therefore require both trial evidence and individual clinical judgment.
Response is usually evaluated through symptoms, physical examination, blood tests, and imaging such as PET/CT. A temporary treatment delay does not automatically mean therapy has failed; delays are often used to allow blood counts, liver tests, swelling, or other toxicities to recover.
Monitoring Before and During Treatment
Before beginning Zynlonta, the oncology team may review previous lymphoma treatments, biopsy findings, CD19-targeted therapies, current infections, liver health, kidney function, pregnancy potential, and plans for CAR T-cell therapy or transplantation.
Monitoring commonly includes:
- Complete blood counts
- Liver-function testing
- Blood glucose
- Albumin and other chemistry results
- Weight and examination for swelling
- Assessment for infection
- Skin examination and questions about sun reactions
- Evaluation of breathing symptoms or chest discomfort
- Periodic lymphoma imaging
Patients should ask whom to call outside normal clinic hours and which symptoms require an emergency department visit. Saving the oncology clinic’s 24-hour number in more than one phone is surprisingly useful healthcare technology.
Practical Experiences During Zynlonta Treatment
The following section summarizes common practical treatment experiences and preparation strategies. It is not a fabricated patient testimonial, and individual experiences vary widely.
Before the first infusion
The first cycle often includes more preparation than patients expect. Blood may be drawn shortly before treatment, medications are reconciled, weight is checked, and the care team confirms that dexamethasone was started correctly. This is a good time to bring an updated medication list rather than relying on memoryespecially when several bottles have names that sound like minor characters from a science-fiction series.
Some people find it useful to pack a light infusion bag containing water, a snack approved by the clinic, a phone charger, warm socks, lip moisturizer, sunscreen, and a written symptom list. The actual infusion is relatively short, but laboratory processing, pharmacy preparation, examination, and observation can make the appointment longer.
During the infusion
Patients are seated or reclined while Zynlonta is delivered through an IV line over approximately 30 minutes. Nurses monitor the line and ask about unusual sensations. Any burning, pain, tightness, itching, or swelling near the IV should be reported immediately because leakage outside the vein may damage tissue.
Some patients feel little during the infusion itself. Others notice fatigue, mild nausea, anxiety, or steroid-related restlessness. Patients should not assume that a quiet infusion predicts an easy week or, conversely, that mild discomfort means the drug is working better. Treatment effectiveness is measured through clinical evaluation and imaging, not by the dramatic quality of infusion day.
The first several days afterward
Dexamethasone may temporarily increase energy, appetite, blood sugar, or wakefulness. When the steroid course ends, some people notice a “crash” in energy. Planning lighter activities for several days can be more realistic than scheduling a heroic return to normal immediately after treatment.
Nausea, appetite changes, diarrhea, constipation, fatigue, muscle aches, or abdominal discomfort may occur. Small meals, adequate fluids, and clinician-approved anti-nausea or bowel medicines can help. Patients should not start herbal “detox” products, high-dose supplements, or aggressive fasting programs to cleanse the drug from the body. Zynlonta is cleared through normal biological processes, and unapproved products may complicate liver function, hydration, nutrition, or drug safety.
Tracking swelling and breathing changes
Because fluid retention is an important Zynlonta risk, some patients are instructed to monitor weight at the same time each day. A written log can reveal a rapid increase that might otherwise feel like ordinary fluctuation. Increasing ankle swelling, tighter shoes, abdominal fullness, a new cough, chest pressure, or shortness of breath should be reported promptly.
Patients should not independently start a leftover diuretic or sharply restrict fluids unless the oncology team gives specific instructions. Swelling may have several causes, and treating the wrong cause at home can create new problems.
Managing sunlight and skin sensitivity
Sun protection can become a daily treatment task rather than a beach-only ritual. Photosensitivity may occur even during routine errands or while sitting near a bright window. Protective sleeves, a hat, shade, sunscreen, and avoiding midday sun can reduce exposure.
A mild rash should still be photographed and reported because appearance can change before the next appointment. A severe, painful, blistering, peeling, or rapidly spreading reaction needs urgent evaluation. Patients should avoid applying unfamiliar medicated creams until the care team has reviewed the rash.
Blood-count timing and infection precautions
Low blood counts may develop even when a patient initially feels well. Hand hygiene, avoiding close contact with people who are actively ill, food-safety precautions, and prompt fever reporting are practical defenses. The goal is not to live inside a disinfected bubble; it is to reduce avoidable exposure while recognizing that fever and infection symptoms deserve rapid attention.
Unusual bruising, nosebleeds that are difficult to stop, blood in urine or stool, marked dizziness, or worsening shortness of breath may signal low platelets or anemia. These symptoms should be reported rather than silently attributed to “just cancer fatigue.”
The emotional experience
Starting a third-line or later treatment can bring relief, fear, skepticism, and hope at the same time. Some patients feel encouraged by having an outpatient targeted option. Others worry about whether another treatment will work after previous therapies failed. Both reactions are understandable.
It may help to ask the oncologist what success would look like, when the first scan is expected, what side effects are most likely to cause a delay, and which alternative treatments remain available. Clear milestones can make the treatment period feel less like waiting in fog.
Caregivers can support treatment by maintaining a symptom calendar, attending important visits, watching for subtle confusion or weakness, and helping with transportation after difficult cycles. They should also avoid becoming the household’s unofficial oncology department. Symptoms such as fever, breathing difficulty, jaundice, severe rash, or rapid swelling require professional assessment.
Conclusion
Zynlonta is a CD19-directed antibody-drug conjugate used for certain adults with relapsed or refractory large B-cell lymphoma after at least two previous systemic treatments. It is administered every three weeks, beginning with two higher-dose cycles and continuing at a lower dose in later cycles.
The treatment can produce meaningful responses, including complete responses, in some heavily pretreated patients. Its risks are equally important to understand. Fluid accumulation, capillary leak syndrome, low blood counts, severe infections, liver injury, photosensitive skin reactions, pregnancy harm, and infusion-site tissue damage require careful monitoring.
Patients can make treatment safer by taking dexamethasone exactly as prescribed, attending laboratory appointments, protecting their skin from sunlight, maintaining an updated medication list, and reporting symptoms early. With Zynlonta, the most useful superpower is not toughnessit is timely communication.
Editorial note: Drug labeling and treatment recommendations can change. This content reflects U.S. prescribing information revised in February 2026 and should be reviewed periodically for updates.
